The National Institute of Pharmaceutical Education and Research launches open access publishing hub in India with F1000

By Martha Attard Gialanze August 4, 2021

Discover the new Gateway on F1000Research, enabling a home for the National Institute of Pharmaceutical Education and Research (NIPER-Kolkata) conference outputs.

Today, the National Institute of Pharmaceutical Education and Research (NIPER-Kolkata) launched its own open access publishing hub with F1000, Taylor & Francis Group’s open research publishing arm. This will be hosted on the F1000Research site, adopting its pioneering approach to open science publishing.

NIPER-Kolkata, founded in 2007 as a centre of excellence for higher education, research and development in Pharmaceutical Sciences, will be adopting F1000’s open science practices to increase the reproducibility and accessibility of their published research. This means the research is free for anyone to read and will use the innovative F1000Research publishing model that combines the benefits of rapid publication with mechanisms to assure quality and transparency, thereby accelerating research impact.

The NIPER-Kolkata gateway provides a home for their conference-linked outputs, enabling their scientific outcomes to be published open access. This gateway welcomes submissions from the fields of, drug discovery, process chemistry, pharmacological studies, natural products, pharmaceutical formulation, computational studies, and medical devices, published in all forms, from traditional research articles, to a protocols, registered report, data notes, case studies, and much more.

Dr.V.Ravichandiran, Director, National Institute of Pharmaceutical Education and Research said:

“The National Institute of Pharmaceutical Science (NIPER), Kolkata, is very pleased to partner with F1000 to make our open science aspirations a reality. We are excited to openly present our academic endeavours to the scientific community, to enable real-world impact with our research and look forward to seeing our researchers embrace this new way of publishing.”

Rebecca Lawrence, Managing Director, F1000 said:

“We continue to deepen our commitment to open research through this partnership with NIPER-Kolkata, supporting academic collaboration and discovery at scale, globally. The leadership shown by NIPER-Kolkata in its desire to embrace open research publishing practices is a significant step forward for open science in India.”

The NIPER-Kolkata gateway is now open for submissions: Any article with a co-author at NIPER-Kolkata is eligible.

About F1000

F1000 fosters a culture of innovation to accelerate the reach of knowledge and put it in the hands of those who will shape the future.  

We provide open research publishing solutions and services to organizations such as the European Commission, Wellcome, and the Bill & Melinda Gates Foundation, as well as directly to researchers through our own publishing platform, F1000Research.

F1000 is wholly owned by the Taylor & Francis Group, an Informa Group company

About NIPER-Kolkata

The National Institute of Pharmaceutical Education and Research, Kolkata (NIPER-K) was created in 2007 under the aegis of Ministry of Chemicals & Fertilizer as a centre of excellence for higher education, research and development in Pharmaceutical Sciences. This followed the establishment of NIPER Mohali, which is the first national level institute in pharmaceutical sciences with a proclaimed objective of becoming a centre of excellence for advanced studies and research in pharmaceutical sciences. NIPERs are conceived to provide leadership in pharmaceutical sciences and related areas not only within the country, but also to the countries in South East Asia, South Asia, and Africa.

NIPER is a member of the Association of Indian Universities and Association of Commonwealth Universities to become a globally recognized brand. The main objective of the institute is to offer the following programs: M.S. (Pharm.) and Ph.D.

Further information about NIPER Kolkata can be found at:


Martha Attard Gialanze,

Corporate Communications Executive,


We use cookies to improve your website experience. To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy. By closing this message, you are consenting to our use of cookies.